CoChat

BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Meta-analysis of Randomized Controlled Trials

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

PURPOSE: To evaluate the relative efficacy and safety of bevacizumab versus ranibizumab for the treatment of the neovascular form of age-related macular degeneration. METHODS: A comprehensive literature search using the Cochrane Methodology Register to identify randomized controlled trials comparing bevacizumab with ranibizumab in patients with neovascular age-related macular degeneration. Efficacy estimates were determined by comparing weighted mean differences in the change of best-corrected visual acuity and central macular thickness from baseline. Safety estimates were determined by calculating the risk ratio for rates of death, arteriothrombotic events, venous thrombotic events, and at least 1 serious systemic adverse event. Statistical analysis was performed using the RevMan 5.1 software. RESULTS: A total of 6 randomized controlled trials were selected for this meta-analysis, including 2,612 patients (1,292 patients in the bevacizumab group and 1,320 patients in the ranibizumab group). There were no significant differences between bevacizumab and ranibizumab in best-corrected visual acuity mean change at 1 year or 2 years (weighted mean difference = -0.40, 95% confidence interval [CI], -1.48 to 0.69, P = 0.47 and weighted mean difference = -1.16, 95% CI, -2.82 to 0.51, P = 0.17, respectively). Ranibizumab was found to be more efficacious in reducing central macular thickness at 1 year (weighted mean difference = 4.35, 95% CI, 0.92-7.78, P = 0.01). The pooled risk ratios comparing the rates of serious systemic adverse events at 1 year and 2 years were slightly in favor of ranibizumab (risk ratio = 1.24, 95% CI, 1.04-1.48, P = 0.02 and risk ratio = 1.20, 95% CI, 1.05-1.37, P = 0.008, respectively), whereas the rates of death, arteriothrombotic events, and venous thrombotic events did not differ statistically. CONCLUSION: Bevacizumab and ranibizumab had equivalent efficacy for best-corrected visual acuity in the treatment of neovascular age-related macular degeneration. Ranibizumab tended to have a better anatomical outcome. There were no differences between drugs in rates of death, arteriothrombotic events or venous thrombotic events, and differences in rates of serious systemic adverse events that require further study.

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0000000000000301

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 3

  1. Jadad, 1996, Carroll D, et al.., Assessing the quality of reports of randomized clinical trials: is blinding necessary Control Clin Trials, 17, 1
  2. Beaumont, 2011, Bevacizumab: not as good with more adverse reactions Clin Experiment O, phthalmol, 39, 588
  3. Lim, 2011, Mitchell P, et al.., Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned Am J Ophthalmol, 152, 329

Cited by

See all 39

Metadata

Authors
Chen, G., Li, W., Tzekov, R., Jiang, F., Mao, S., & Tong, Y.
Affiliations
  • Xiamen University (CN)
  • University of South Florida (US)
  • Quzhou City People's Hospital (CN)
Corresponding author
  • Chen, Guohai
  • Jiang, Fangzheng
  • Mao, Sihong
  • Tong, Yuhua
Venue
Retina
Published
2015-02
Volume
35
Issue
2
Pages
187-193
ISSN
0275-004X (ISSN-L)
OpenAlex
W2036703870
Cited by
36
References
25
Citations by year
2026: 1 · 2025: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 5 · 2015: 5
FWCI
6.25
Type
journal article
Language
en
Open access
closed
Locations
  • Retina (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
bevacizumab, ranibizumab, neovascular age-related macular degeneration, anti-VEGF therapy, best-corrected visual acuity, central macular thickness, treatment safety and efficacy comparison, intravitreal injection
MeSH terms
Bevacizumab, Ranibizumab, Humans, Visual Acuity, Randomized Controlled Trials as Topic, Treatment Outcome, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Meta-analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1097/iae.0000000000000301
The paper
Chen, G., Li, W., Tzekov, R., Jiang, F., Mao, S., & Tong, Y. (2015). BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Meta-analysis of Randomized Controlled Trials. Retina. https://doi.org/10.1097/iae.0000000000000301

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.